USFDA issues 7 observations for Natco Pharma's Hyderabad plant after Nov inspection

Share:
Audio Loading voice…
USFDA issues 7 observations for Natco Pharma's Hyderabad plant after Nov inspection

Synopsis

The USFDA has handed Natco Pharma a seven-observation Form 483 after a nine-day inspection of its Kothur, Hyderabad facility — arriving just as the company battles a 60.8% year-on-year profit drop and a 40% two-year stock decline. How management responds to the regulator will be the next critical test for a pharma firm already under financial strain.

Key Takeaways

USFDA issued a Form 483 with seven observations after inspecting Natco Pharma's Kothur, Hyderabad plant between 12–20 November 2026 .
Natco Pharma describes the observations as procedural and says it expects no major compliance concerns .
In Q2 FY27 , the company's net profit fell 60.8 per cent YoY to ₹203 crore ; revenue dropped 29 per cent to ₹967 crore .
EBITDA declined 55.4 per cent from ₹579 crore in the year-ago quarter.
The stock closed at ₹817 on the BSE , down about 40 per cent over two years from a 52-week high of ₹1,216.29 .

Natco Pharma on Saturday, 21 November 2026, disclosed that the US Food and Drug Administration (USFDA) has issued seven observations following an inspection of its manufacturing facility at Kothur, Hyderabad. The company said it views the observations as procedural and does not anticipate major compliance concerns.

Inspection Details

The USFDA conducted its inspection of the Kothur facility between 12 November and 20 November, according to a regulatory filing by the company. At the conclusion of the inspection, the regulator issued a Form 483 containing the seven observations.

A Form 483 is issued under USFDA procedures when investigators identify conditions that, in their judgement, may constitute potential violations of regulatory requirements and warrant management's attention. The company did not disclose further details of the specific observations.

Company's Response

Natco Pharma expressed confidence in its ability to resolve the flagged issues. 'The company believes that the observations are procedural in nature and is confident of addressing these observations comprehensively within stipulated timelines,' the company stated in its regulatory filing.

Notably, the company's assertion that the observations carry no major compliance risk will be closely watched by investors, given that Form 483 notices — while not automatically resulting in import alerts or warning letters — can escalate if management responses are deemed inadequate by the regulator.

Financial Performance Under Pressure

The USFDA development comes against a backdrop of weakening financials. In Q2 FY27, Natco Pharma's net profit declined 60.8 per cent year-on-year to ₹203 crore, compared to ₹518 crore in Q2 FY26. Revenue from operations also fell 29 per cent to ₹967 crore, from ₹1,363 crore in the corresponding quarter of the previous year.

At the operating level, earnings before interest, taxes, depreciation and amortisation (EBITDA) dropped 55.4 per cent from ₹579 crore a year earlier, underscoring the breadth of the company's earnings compression.

Stock Performance

Shares of Natco Pharma on Friday closed 0.55 per cent lower at ₹817 per share on the Bombay Stock Exchange (BSE). The stock has recorded a 52-week high of ₹1,216.29 and a 52-week low of ₹774. According to exchange data, the stock has declined approximately 40 per cent over the last two years.

What to Watch

The company's formal response to the USFDA's Form 483 observations will be a key near-term trigger. Any escalation — such as a warning letter or import alert — could weigh further on the stock and disrupt US market supplies. Industry analysts will also track whether the ongoing revenue decline stabilises in the coming quarters.

Point of View

But it is not trivial either — especially for a company whose earnings are already under severe pressure. Natco Pharma's framing of the findings as 'procedural' is standard corporate boilerplate; the real signal will come from the USFDA's assessment of the company's written response. With a 60.8% profit drop and a stock that has shed 40% over two years, any regulatory escalation would leave very little cushion. The Indian pharma sector's recurring USFDA inspection woes point to a systemic gap between manufacturing scale and quality-system maturity — a gap that individually companies keep claiming to address without the sector-wide data to prove it.
NationPress
21 Nov 2026

Frequently Asked Questions

What is a USFDA Form 483 and why was it issued to Natco Pharma?
A USFDA Form 483 is a list of observations issued at the end of an inspection when investigators identify conditions that may constitute potential regulatory violations. It was issued to Natco Pharma after a nine-day inspection of its Kothur, Hyderabad manufacturing facility between 12 and 20 November 2026, covering seven observations.
Is Natco Pharma's plant at risk of an import ban or warning letter?
The company has stated it does not expect major compliance concerns and plans to address all observations within stipulated timelines. However, escalation to a warning letter or import alert remains possible if the USFDA finds the company's response inadequate; no such action has been announced as of this report.
How has Natco Pharma's financial performance been recently?
In Q2 FY27, Natco Pharma reported a 60.8 per cent year-on-year drop in net profit to ₹203 crore, while revenue from operations fell 29 per cent to ₹967 crore. EBITDA also declined 55.4 per cent, reflecting broad-based earnings compression.
How has Natco Pharma's stock performed?
Natco Pharma shares closed at ₹817 on the BSE on Friday, down 0.55 per cent on the day. The stock has a 52-week high of ₹1,216.29 and has lost approximately 40 per cent of its value over the past two years, according to exchange data.
What happens next after a Form 483 observation?
After receiving a Form 483, the company typically submits a written response to the USFDA within 15 business days, detailing corrective actions. The regulator then evaluates the response and decides whether to close the matter, issue a warning letter, or take further enforcement action.
Nation Press
The Trail

Connected Dots

Tracing the thread behind this story — newest first.

8 Dots
  1. Latest 1 week ago
  2. 3 months ago
  3. 3 months ago
  4. 6 months ago
  5. 6 months ago
  6. 7 months ago
  7. 8 months ago
  8. 11 months ago
Google Prefer NP
On Google